蚓激酶联合阿托伐他汀治疗脑梗死患者颈动脉斑块的临床研究

目的:探讨蚓激酶联合阿托伐他汀治疗脑梗死患者颈动脉粥样硬化的临床疗效。方法:选择脑梗死患者188例,应用彩色多普勒超声检查患者颈总动脉、颈内动脉颅外段及分叉处内-中膜厚度(Intima-medial Thickness IMT)。将颈动脉内-中膜厚度≥1.2mm或有粥样硬化斑块形成定义为颈动脉斑块。所有入选患者随机分为2组:蚓激酶+阿托伐他汀组(治疗组)和阿托伐他汀组(对照组)。比较两组的治疗效果。结果:治疗前后治疗组患者血浆纤维蛋白原及D-二聚体水平明显变化(P<0.05)。188例脑梗死患者中治疗组90例,显效39例(43.3%),对照组98例,显效19例(19.3%)。结论:蚓激酶联合阿托伐他汀治疗可以明显改善脑梗死患者颈动脉粥样硬化程度。

A Clinical Study On the Treatment of Carotid Plaque of Cerebral Infarction Patients with Lumbrokinase and Atorvastatin

Objective: To investigate the clinical efficacy in the treatment of carotid plaque of cerebral infarction patients with Lumbrokinase and Atorvastatin. Methods: Carotid intimamedia thickness(IMT) was measured by color Doppler ultrasonography in 188 patients with cerebral infarction. we defined IMT> 1.2mm and plaque as carotid plaque. All patients were divided into two groups: the treatment group and the control group(P<0.05). Results: The level of fibrinogen and D-dimer was changed in the treatment group; There were 39 patients(43.3%) in the treatment group, and 37 patients(19.3%) in the control group. Conclusions: The clinical efficacy in the treatment of carotid plaque of cerebral infarction patients with Lumbrokinase and Atorvastatin is clear.